Clinical Outcomes of Administration of Rituximab for Desensitization in Liver Transplant Patients with Preformed Donor-Specific Antibodies: A Single-Center Experience

Masato Shizuku; Nobuhiko Kurata; Kanta Jobara; Yasuhiro Fujimoto; Yasuhiro Ogura

doi:10.12659/AOT.941456

15 December 2023 : Original article

Clinical Outcomes of Administration of Rituximab for Desensitization in Liver Transplant Patients with Preformed Donor-Specific Antibodies: A Single-Center Experience

Masato Shizuku

^123ABCDEF*, Nobuhiko Kurata

^1B, Kanta Jobara

^1B, Yasuhiro Fujimoto

^1B, Yasuhiro Ogura

^1ABCDFG

DOI: 10.12659/AOT.941456

Ann Transplant 2023; 28:e941456

Authors information Article notes Copyright and License information

Background Material and Methods Results Discussion Conclusions References

Related articles Order reprints Share article Share by email

View HTML version

Figure 2 MFI changes of pDSA after liver transplantation. (A) MFI changes in pDSA class I in the rituximab (+) group. (B) MFI changes in pDSA class II in the rituximab (+) group. (C) MFI changes in pDSA class I in the rituximab (−) group. (D) MFI changes in pDSA class II in rituximab (−) group. MFI – mean fluorescence index; pDSA – preformed donor-specific antibody.

Back to the Article

Clinical Outcomes of Administration of Rituximab for Desensitization in Liver Transplant Patients with Preformed Donor-Specific Antibodies: A Single-Center Experience

Your Privacy